Mirum Pharmaceuticals Says FDA Approves Tablet Formulation of Treatment for Cholestatic Pruritus

Important legal information about the email you will be sending. By using this service, you agree to input your real email address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an email. All information you provide will be used by Fidelity solely for the purpose of sending the email on your behalf. The subject line of the email you send will be "Fidelity.com: "

Mirum Pharmaceuticals Says FDA Approves Tablet Formulation of Treatment for Cholestatic Pruritus

, MT Newswires - 10:26 AM ET 4/14/2025 default

10:26 AM EDT, 04/14/2025 (MT Newswires) -- Mirum Pharmaceuticals ( MIRM ) said Monday the US Food and Drug Administration has approved a new tablet formulation of Livmarli to treat cholestatic pruritus in patients with Alagille syndrome and Progressive Familial Intrahepatic Cholestatis.

Livmarli tablets are expected to be available through Mirum Access Plus in June, the company said.

Price: 39.56, Change: -0.02, Percent Change: -0.06

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.